Retinoic acid (RA), the major bioactive metabolite of retinol or vitamin A, induces a spectrum
of pleiotropic effects in cell growth and differentiation that are relevant for embryonic …

Valproic acid (VPA), a branched short‐chain fatty acid, is widely used as an antiepileptic
drug and a mood stabilizer. Antiepileptic properties have been attributed to inhibition of …

The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical
characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a …

Cancer drug resistance is an enormous problem. It is responsible for most relapses in
cancer patients following apparent remission after successful therapy. Understanding …

Histone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a
group of targeted anticancer agents. The first of these new HDACi, vorinostat …

Acute leukaemias are characterized by recurring chromosomal aberrations and gene
mutations that are crucial to disease pathogenesis. It is now evident that epigenetic …

Over the last 5 years, a plethora of histone deacetylase inhibitors (HDACi) have been
evaluated in clinical trials. These drugs have in common the ability to hyperacetylate both …

We conducted a phase 1/2 study of the combination of 5-aza-2′-deoxycytidine (decitabine)
and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced …

The combination of a DNA hypomethylating agent with a histone deacetylase inhibitor has
synergistic antileukemia activity and may restore sensitivity to all-trans retinoic acid (ATRA) …

Histone deacetylase (HDAC) inhibitors are a new class of targeted anticancer agents.
Several HDAC inhibitors are in clinical trials and have shown significant activity against a …